Enrique Grande, One Oncology Madrid Program Director at Quironsalud, shared on X:
“Phase 2 trial in RCC with inferior vena cava tumor thrombus: neoadjuvant stereotactic ablative radiotherapy (SAbR) followed by surgery (n=23).
1-year recurrence-free survival: 71.4% above the 55.7% historical benchmark. Thrombus downstaging in 22%.
A promising approach for one of the most challenging complications in kidney cancer.”
Title: Neoadjuvant Stereotactic Ablative Radiotherapy Before Inferior Vena Cava Thrombectomy for Renal Cell Carcinoma: A Phase 2 Nonrandomized Clinical Trial
Authors: Raquibul Hannan, Lin Lin, Ryan Assadi, Laurentiu M. Pop, Lily Robles, Faya Zhang, Oscar Mulvaney, Ang Gao, Payal Kapur, Ivan Pedrosa, Aurelie Garant, Daniel Yang, Chul Ahn, Michael Wait, Robert Timmerman, Vitaly Margulis
You can also read:
Raquibul Hannan: Encouraging Phase 2 Results for Neoadjuvant SAbR in RCC With IVC Tumor Thrombus
